Verapamil as an antiarrhythmic agent in congestive heart failure: Hopping from rabbit to human?

British Journal of Pharmacology

Volumn 166, Issue 2, 2012, Pages 554-556

  Stams, Thom R G ^a   Bourgonje, Vincent J A ^a   Vos, Marc A ^a   Van Der Heyden, Marcel A G ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

arrhythmia; calcium channel; heart failure; rabbit model; repolarization reserve; torsade de pointes; verapamil

Indexed keywords

CALCIUM CHANNEL BLOCKING AGENT; NIFEDIPINE; VERAPAMIL;

ANTIARRHYTHMIC ACTIVITY; ATRIOVENTRICULAR BLOCK; CONGESTIVE HEART FAILURE; DISEASE PREDISPOSITION; DRUG BLOOD LEVEL; DRUG DOSE TITRATION; DRUG EFFECT; HEART ARRHYTHMIA; HEART REPOLARIZATION; HEART VENTRICLE TACHYCARDIA; HUMAN; NONHUMAN; POLYMORPHIC VENTRICULAR TACHYCARDIA; PRIORITY JOURNAL; QT PROLONGATION; RABBIT; REVIEW; RISK FACTOR; TORSADE DES POINTES;

ANIMALS; ANTI-ARRHYTHMIA AGENTS; DISEASE MODELS, ANIMAL; HEART FAILURE; HUMANS; RABBITS; VERAPAMIL;

EID: 84859882900     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/j.1476-5381.2011.01818.x     Document Type: Review

References (11)

1. Bourgonje VJ, Vos MA, Ozdemir S, Doisne N, Acsai K, Bito V, et al,. (2011). SEA0400 provides anti-arrhythmic actions against dofetilide-induced torsade de pointes (TdP) without a negative inotropic effect. Heart Rhythm 8: S330-S331.
2. Chew CY, Hecht HS, Collett JT, McAllister RG, Singh BN, (1981). Influence of severity of ventricular dysfunction on hemodynamic responses to intravenously administered verapamil in ischemic heart disease. Am J Cardiol 47: 917-922. (Pubitemid 11150938)
3. Frommeyer G, Milberg P, Witte P, Stypmann J, Koopmann M, Lücke M, et al,. (2011). A new mechanism preventing proarrhythmia in chronic heart failure: rapid phase-III repolarization explains the low proarrhythmic potential of amiodarone in contrast to sotalol in a model of pacing-induced heart failure. Eur J Heart Fail 13: 1060-1069.
4. Janse MJ, (2004). Electrophysiological changes in heart failure and their relationship to arrhythmogenesis. Cardiovasc Res 61: 208-217. (Pubitemid 38091761)
5. Ca block leads to suppression of early afterdepolarizations and reduction of transmural dispersion of repolarization in a whole heart model of chronic heart failure. Br J Pharmacol 166: 557-568.
6. Milberg P, Frommeyer G, Uphaus T, Kaiser D, Osada N, Breithardt G, et al,. (2012b). Electrophysiologic profile of dronedarone on the ventricular level: beneficial effect on post repolarization refractoriness in the presence of rapid phase-III-repolarization. J Cardiovasc Pharmacol 59: 92-100.
7. Millard RW, Grupp G, Grupp IL, DiSalvo J, DePover A, Schwartz A, (1983). Chronotropic, inotropic, and vasodilator actions of diltiazem, nifedipine, and verapamil. A comparative study of physiological responses and membrane receptor activity. Circ Res 52: I29-I39.
8. Oros A, Houtman MJ, Neco P, Gomez AM, Rajamani S, Oosterhoff P, et al,. (2010). Robust anti-arrhythmic efficacy of verapamil and flunarizine against dofetilide-induced TdP arrhythmias is based upon a shared and a different mode of action. Br J Pharmacol 161: 162-175.
9. Roden DM, (2004). Drug-induced prolongation of the QT interval. N Engl J Med 350: 1013-1022. (Pubitemid 38269278)
10. Thomsen MB, Matz J, Volders PG, Vos MA, (2006). Assessing the proarrhythmic potential of drugs: current status of models and surrogate parameters of torsades de pointes arrhythmias. Pharmacol Ther 112: 150-170. (Pubitemid 44301487)
11. Varrõ A, Baczkõ I, (2011). Cardiac ventricular repolarization reserve: a principle for understanding drug-related proarrhythmic risk. Br J Pharmacol 164: 14-36.